多替拉韦钠治疗方案在加蓬恩肯博门诊治疗中心艾滋病毒/艾滋病患者中的疗效。
Effectiveness of dolutegravir-based treatment among HIV/AIDS patients in Nkembo Outpatient Treatment Center, Gabon.
作者信息
Mangala Christian, Moukanda-Ifoundou Rolf, Maulot-Bangola Denis, Moutsinga Alain, Mombo-Maganga Christian, Okolongo-Mayani Serge Christian, Ongali Brice, Lemamy Guy Joseph, Massolou-Outata Rachyda
机构信息
Catholic University of Central Africa, Yaoundé, Cameroon.
Outpatient Treatment Center of Nkembo, Libreville, Gabon.
出版信息
AIDS Res Ther. 2025 May 3;22(1):50. doi: 10.1186/s12981-025-00744-6.
BACKGROUND
HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment. This study aimed to determine the effectiveness rate of dolutegravir-based treatment among HIV/AIDS patients.
METHODS
A retrospective observational study was conducted among HIV/AIDS patients who started antiretroviral treatment since 48 weeks of follow-up.
RESULTS
The effectiveness rate of dolutegravir-based treatment was 85.1%. HIV/AIDS patients with a CD4 + count below 200 cel/mm, singles, and HIV/AIDS patients whose treatment duration exceeded 12 months were at risk and likely to have an active infection (P = 0.0001).
CONCLUSION
Dolutegravir-based treatment remains effective among HIV/AIDS patients treated at the Nkembo Outpatient Treatment Center.
背景
艾滋病毒/艾滋病治疗继续为全球改善艾滋病毒/艾滋病患者的健康做出巨大贡献。在加蓬，多替拉韦用于艾滋病毒/艾滋病患者的一线治疗。本研究旨在确定基于多替拉韦的治疗在艾滋病毒/艾滋病患者中的有效率。
方法
对自随访48周以来开始抗逆转录病毒治疗的艾滋病毒/艾滋病患者进行回顾性观察研究。
结果
基于多替拉韦的治疗有效率为85.1%。CD4 + 细胞计数低于200个/立方毫米的艾滋病毒/艾滋病患者、单身患者以及治疗持续时间超过12个月的艾滋病毒/艾滋病患者有风险且可能发生活动性感染（P = 0.0001）。
结论
在恩肯博门诊治疗中心接受治疗的艾滋病毒/艾滋病患者中，基于多替拉韦的治疗仍然有效。
Zotero 插件